Maravai LifeSciences Holdings, Inc. (MRVI) Stock

Maravai LifeSciences Holdings, Inc. is a dynamic life sciences company at the forefront of enabling the development of innovative drug therapies, diagnostics, and vaccines globally. Established in 2020 and headquartered in San Diego, California, Maravai offers a comprehensive range of products essential for biopharmaceutical development. Its offerings span nucleic acids utilized in diagnostic and therapeutic applications, antibody-based products crucial for detecting impurities in biopharmaceutical production, and solutions for protein expression analysis across various species.

The company operates through two main segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and supplying essential reagents for gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This includes messenger RNA, oligonucleotides, and proprietary CleanCap capping technology, supporting critical processes in DNA and RNA synthesis, modification, labeling, and purification.

In the Biologics Safety Testing segment, Maravai provides analytical products crucial for biologic manufacturing process development. These offerings include custom antibody and assay development services, HCP ELISA kits, bioprocess impurity and contaminant ELISA kits, as well as a range of ancillary reagents and customized services. Maravai serves a diverse customer base encompassing biopharmaceutical companies, life sciences research organizations, academic institutions, and in vitro diagnostics firms, underscoring its pivotal role in advancing scientific discovery and therapeutic innovation worldwide.